Allianz Asset Management
ABEO icon

Allianz Asset Management’s Abeona Therapeutics ABEO Stock Holding History

Allianz Asset Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-4,265
Closed -$761K – 2654
2018
Q4 		$761K Sell
4,265
-161
-4% -$35.1K ﹤0.01% 2137
2018
Q3 		$1.42M Buy
4,426
+379
+9% +$134K ﹤0.01% 2088
2018
Q2 		$1.62M Sell
4,047
-19
-0.5% -$8.3K ﹤0.01% 2028
2018
Q1 		$1.46M Sell
4,066
-30
-0.7% -$11.1K ﹤0.01% 2062
2017
Q4 		$1.62M Sell
4,096
-53
-1% -$21.9K ﹤0.01% 2090
2017
Q3 		$1.77M Sell
4,149
-759
-15% -$204K ﹤0.01% 2051
2017
Q2 		$785K Sell
4,908
-142
-3% -$19.4K ﹤0.01% 2294
2017
Q1 		$631K Buy
5,050
+3,107
+160% +$401K ﹤0.01% 2357
2016
Q4 		$236K Buy
+1,943
New +$304K ﹤0.01% 2505

Other funds holding ABEO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Allianz Asset Management's ABEO Position: Q1 2019 in Review

Allianz Asset Management sold out of Abeona Therapeutics (ABEO) in Q1 2019, closing a stake of 4,265 shares — an estimated $761K sold.

Allianz Asset Management first reported a position in ABEO in Q4 2016 and held it in 9 quarters. The position peaked at $1.77M in Q3 2017. 87 funds tracked by Wall St. Rank hold ABEO as of Q1 2019.

  • Allianz Asset Management reported no remaining Abeona Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Allianz Asset Management sold 4,265 Abeona Therapeutics shares in Q1 2019, an estimated $761K.
  • Allianz Asset Management first reported a position in Abeona Therapeutics in Q4 2016 and held it in 9 quarters.
  • Allianz Asset Management's Abeona Therapeutics position peaked at $1.77M in Q3 2017.
  • 87 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2019.

Based on Allianz Asset Management's 13F filing for Q1 2019, filed 13 May 2019.